Introduction {#sec1-1}
============

The worldwide emergence of multidrug-resistant bacterial strains in hospitals and community continues to be a problem of due scientific concern, especially infections caused by *Pseudomonas* species and Pseudomonas aeruginosa in particular.\[[@ref1]\] *Pseudomonas* spp. are one of the most common gram-negative pathogens associated with infections and show a high level of intrinsic resistance to antimicrobial drugs and an ability to become even more drug-resistant.\[[@ref2][@ref3]\] These characteristics are caused by selective pressure of mutations in chromosomal genes that lead to production of extended-spectrum beta-lactamase (ESBL) and AmpC hyperexpression, repression or inactivation of oprD, and overexpression of efflux pumps.\[[@ref3]\] In addition, *Pseudomonas* spp. are able to acquire other drug-resistant determinants by horizontal transfer of mobile genetic elements coding for class B carbapenemases (also called metallo-β-lactamases \[MBLs\]).\[[@ref4]\] *Pseudomonas* spp. may also acquire resistance to antibiotics due to permeability barrier of the cell surface in the form of biofilm production. Biofilm-producing organisms are far more resistant to antimicrobial agents than organisms which do not. In some extreme cases, the concentrations of antimicrobials required to achieve bactericidal activity against adherent organisms can be three- to four-fold higher than for those bacteria which do not produce biofilm, depending on the species and drug combination.\[[@ref5]\] The versatility and ability of *Pseudomonas* spp. to combine different resistance mechanisms have led to emergence of strains that are resistant to multiple antimicrobial drugs, which severely limits therapeutic options for treating infections.\[[@ref6]\] This emphasizes the need for the detection of isolates that produce these enzymes to avoid therapeutic failures and nosocomial outbreaks.

Pseudomonas Aeruginosa {#sec1-2}
======================

*Pseudomonas aeruginosa* is an important conditioned pathogen, which is known to cause nosocomial septicemia and burn infections, which are very difficult to treat particularly in the burn wards.\[[@ref7][@ref8]\] Extended spectrum beta-lactamases (ESBLs)-producing *P. aeruginosa* pose a serious threat as a healthcare-associated infections.\[[@ref9]\] Since the discovery of ESBLs in 1983, their prevalence has been reported threateningly in many regions of the world and now comprises over three hundred variants.\[[@ref10]\]

When inappropriate antimicrobial therapy is used to treat infections caused by ESBL-producing bacteria, failure in the clinical treatment will occur frequently.\[[@ref11]\] *P. aeruginosa* infrequently found as part of the human microflora in healthy individuals is a gram-negative, non-glucose fermenter rod. It is the primary cause of ventilator-associated pneumonia in the intensive care unit.\[[@ref12][@ref13]\] In recent years, nosocomial infections caused by *P. aeruginosa* have been recognized as an acute problem in hospitals due to its intrinsic resistance to many antibiotic classes and its capacity to acquire practical resistance to all effective antibiotics.\[[@ref14]\] Presently, genetic techniques supported by phenotypic tests enabled us to be informed of a detailed characteristic of strains isolated from clinical and environmental wards.\[[@ref15]\] To determine the genetic relationship between clinical and environmental isolates of *P. aeruginosa*, there are some techniques such as restriction endonucleases analysis, multilocus enzyme electrophoresis, biotyping, pulsefield gel electrophoresis, and ribotyping. Among them, the PCR-ribotyping is an efficient technique used during last 10 years and based on the amplification of spacer regions or intervening sequences between 16S and 23S rDNA genes.\[[@ref16]\] There are some previous studies in Iran about the role of *P. aeruginosa* in nosocomial infection; Khorvash *et al*. study indicates that there are good tools to detect *P. aeruginosa* nosocomial infection by procalcitonin (PCT) and C-reactive protein (CRP)\[[@ref17]\] and Japoni *et al*. study showed that there are some difficulty in the treatment of multi-drug resistant (MDR) *P. aeruginosa*.\[[@ref18]\]

Extended Spectrum Beta-Lactamase (Esbl) {#sec1-3}
=======================================

ESBL are relatively group of plasmid-mediated enzymes. The first ESBL, an oxyimino beta-lactamase, was described in 1983 in Frankfurt, Germany.\[[@ref19]\] These are enzymes that mediate resistance to extended-spectrum cephalosporins, carbapenums, and monobactums but do not affect cephamycins (cefoxitin and cefotetan) and carbapenems (meropenem or imipenem).\[[@ref20]\] The overall prevalence of beta-lactamases and in particular the ESBL is rising with increased usage of higher generation cephalosporins and is presenting a major challenge.\[[@ref21]\]

Types of extended-spectrum beta-lactamase production {#sec2-1}
----------------------------------------------------

### TEM beta-lactamases (class A) {#sec3-1}

TEM-1 is the most commonly encountered beta-lactamase in Gram-negative bacteria. Up to 90% of ampicillin resistance in *E. coli* is due to the production of TEM-1.\[[@ref22]\] The amino acid substitutions responsible for the ESBL phenotype cluster around the active site of the enzyme and change its configuration, allowing access to oxyimino-beta-lactam substrates. Based upon different combinations of changes, currently 140 TEM-type enzymes have been described. TEM-10, TEM-12, and TEM-26 are among the most common in the US.\[[@ref23][@ref24][@ref25]\]

### SHV beta-lactamases (class A) {#sec3-2}

SHV-1 shares 68% of its amino acids with TEM-1 and has a similar overall structure. The SHV-1 beta-lactamase is most commonly found in *K. pneumoniae* and is responsible for up to 20% of the plasmid-mediated ampicillin resistance in this species. ESBLs in this family also have amino acid changes around the active site, most commonly at positions 238 or 238 and 240. More than 60 SHV varieties are known. SHV-5 and SHV-12 are among the most common.\[[@ref23]\]

### CTX-M beta-lactamases (class A) {#sec3-3}

CTX-M-14, CTX-M-3, and CTX-M-2 are the most widespread. CTX-M-15 is currently (2006) the most widespread type in *E. coli* in the UK and is widely prevalent in the community.\[[@ref26]\] An example of beta-lactamase CTX-M-15, along with IS*Ecp1*, has been found to have recently transposed onto the chromosome of *Klebsiella pneumoniae* ATCC BAA-2146.\[[@ref27]\]

OXA beta-lactamases (class D) were long recognized as a less common but also plasmid-mediated beta-lactamase variety that could hydrolyze oxacillin and related anti-staphylococcal penicillins. Other plasmid-mediated ESBLs, such as PER, VEB, GES, and IBC beta-lactamases, have been described but are uncommon and have been found mainly in *P. aeruginosa* and at a limited number of geographic sites.

### Antibiotic resistance {#sec3-4}

*Pseudomonas* is a gram negative bacteria so are naturally resistant to penicillin and beta-lactam antibiotics, and mostly sensitive to piperacillin, imipenem, ticarcillin, or ciprofloxacin.\[[@ref28]\] *P. aeruginosa* is increasingly recognized as an emerging opportunistic pathogen of clinical relevance. One of its most worrying characteristics is its low antibiotic susceptibility.\[[@ref29]\] Some recent studies have shown that phenotypic resistance associated to biofilm formation or to the emergence of small-colony-variants may be important in the response of *P. aeruginosa* populations to antibiotic treatment.\[[@ref30]\]

Aim and Objectives {#sec1-4}
==================

Aim: To study the ESBL production among clinical isolates of *Pseudomonas* spp. by phenotypic methods.

Objectives:

To isolate *Pseudomonas* spp. from various clinical samplesTo identify the antimicrobial susceptibility of *Pseudomonas* spp.To detect ESBL productions by *Pseudomonas* spp.

Materials and Method {#sec1-5}
====================

This study is a prospective study conducted in the Department of Microbiology on 100 *Pseudomonas* spp. isolated from various clinical samples of OPD and IPD. Sample showing growth of *Pseudomonas* spp. was inclusion criterion and cases other than *Pseudomonas* spp. were exclusion criteria. Ethical clearance was taken from ethical committee of Institute.

Inoculation of samples {#sec2-2}
----------------------

All isolates were routinely cultured on MacConkey\'s and blood agar plates as shown in Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. These plates were routinely incubated at 37°C aerobically and after overnight incubation, they were checked for bacterial growth. The organisms were identified as per standard laboratory methods of identification.\[[@ref31]\]

![*Pseudomonas* on blood agar](JFMPC-9-683-g001){#F1}

![*Pseudomonas* on MacConkey agar](JFMPC-9-683-g002){#F2}

Organism identified were confirmed by putting up biochemical test. Antibiotic sensitivity test was done by Kirby Bauer disc diffusion method on Muller Hinton agar (MHA) according to the National Committee for the clinical Laboratory Standard.

Detail of sample collection and sample processing are given in Annexure 2 and Annexure 3, respectively.

Colony morphology {#sec2-3}
-----------------

The colonies were studied for following characters:

Pigment production: The presence of the blue phenazine pigment pyocynin, pyorubrin, and pyoverdin was absolute confirmation of organism. Pigment diffuses into the medium. Pyoverdin (fluorescein), pyorubrin, and pyomelanin were also produced by *Pseudomonas* spp. Some stains were non-pigmented.Size and shape: large 2--3 mm in diameter, irregularly round.Surface: moist, smooth.Structure: irregularly round.Edges: irregular.Contour: flat, spreading.Consistency: sometimes mucoid.Opacity: translucentIridescence: many strain exhibit a moth-eaten type of colonial lysis with a metallic sheen known as iridescence.Hemolysis: often the presence of hemolysis around the colonies.Emulsifiability : emulsifiable in normal salineCharacteristic Smell: grape-like odor of amino-acetophenone produced from tryptophan.

Morphology and staining characters of non-lactose fermenting colonies on MacConkey\'s agar were studied by gram\'s staining method as shown in [Figure 3](#F3){ref-type="fig"}. The identification of the isolated bacteria was confirmed as being *Pseudomonas* species by studying their motility (hanging drop method or by growing them in semisolid agar medium), pigment production, odor, and by subjecting them to various biochemical tests as shown in Figure [4a](#F4){ref-type="fig"} and [b](#F4){ref-type="fig"}.

![Microscopic view of *Pseudomonas*](JFMPC-9-683-g003){#F3}

![(a) catalase positive *Pseudomonas*. (b) oxidase positive test for *Pseudomonas*](JFMPC-9-683-g004){#F4}

Biochemical confirmation test {#sec2-4}
-----------------------------

Oxidase : positive (+)Catalase: positive (+)Citrate utilization test : citrate utilized (positive)Nitrate reduction test : positive (+)Gelatin liquefaction test,: positive (+)Motility : motileOxidative/fermentative medium: oxidativeTriple sugar iron agar : K/K

Antibiotic susceptibility testing {#sec2-5}
---------------------------------

Antibiotic susceptibility testing was done for all the *Pseudomonas* spp. isolates under the standard CLSI guidelines for the following antimicrobials\[[@ref32]\]:

PiperacilinCiproflaxacinGentamycinAmikacinTobramycinCotrimoxazoleCefoperazoneCefepimeCeftazidimeCeftazidieme + Clavulanic acidMeropenemImipenemColistin.

ESBL detection {#sec2-6}
--------------

ESBL detection was done by phenotypic test, i.e. combined disc diffusion method recommended by CLSI.

Common initial steps.\[[@ref32]\]

Four to five colonies of the test strain were transferred to 1 ml of normal saline to match turbidity to 0.5 McFarland standard.Using this inoculum, lawn culture was made on cation-balanced MHA plate with a sterile cotton swab.Excess broth was expressed by rotating the swab against the inner side of the suspension tube.Inoculum was allowed to dry for 15 min before putting the antibiotic disc.

Phenotypic confirmation test for ESBL was done by ceftazidime and ceftazidime + clavulanic acid on MHA according to CLSI guideline as shown in Figures [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}.\[[@ref31]\]

![*Pseudomonas* on MHA along with antimicrobial discs](JFMPC-9-683-g005){#F5}

![Positive double disk diffusion test for *Pseudomonas* with ceftazidime and cefta + zidime with clavulanic acid](JFMPC-9-683-g006){#F6}

Results {#sec1-6}
=======

Our study shows *Pseudomonas* infection in 54% and 46% in male and female respectively as shown in [Table 1](#T1){ref-type="table"} and [Graph 1](#F7){ref-type="fig"} and 39% of cases were indoor whereas 61% were outdoor patients, as shown in [Tables 2](#T2){ref-type="table"} and [Graph 2](#F8){ref-type="fig"} and infection was predominant in age group 46-60 as shown in [Table 3](#T3){ref-type="table"} and [Graph 3](#F9){ref-type="fig"}. Pseudomonal infection was more in urban population than in rural with maximum rate of Pseudomonal isolated from pus sample as shown in Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"} and Graphs [4](#F10){ref-type="fig"}, [5](#F11){ref-type="fig"}. [Table 6](#T6){ref-type="table"} and [Graph 6](#F12){ref-type="fig"} demonstrates the antibiotic resistance pattern of *Pseudomonas* spp. 88%, 80% resistance was encountered by ceftazidime, cefepime followed by cortimoxazole, and piperacillin showing 61% and, 61% respectively. The antibiotics showing least resistance i.e were gentamycin, meropenem and imepenem, the resistance being 30%, 17% and 15% and colistin is 0% resistance. The rate of ESBL positive samples out of total 100 samples studied 42% were showing ESBL positive *Pseudomonas* while 58% showed non ESBL producing *Pseudomonas* species as shown in [Table 7](#T7){ref-type="table"} and [Graph 7](#F13){ref-type="fig"}. [Table 8](#T8){ref-type="table"} and [Graph 8](#F14){ref-type="fig"} shows distribution of ESBL positive sample in OPD(20%) and IPD(22%). [Table 9](#T9){ref-type="table"} and [Graph 9](#F15){ref-type="fig"} shows gender-wise distribution of *Pseudomonas* from various clinical isolation. Antibiotics resistance pattern of *Pseudomonas* showed high resistance with Cefoperazone, Cefepime and Ceftaziime and Impipenem and Meropenem showed higher antibacterial activities in Cepalosporine and Carbapenem group of antibiotics respectively as in Tables [10](#T10){ref-type="table"}, [11](#T11){ref-type="table"} and Graphs [10](#F16){ref-type="fig"}, [11](#F17){ref-type="fig"}. Out of 100 samples studies, 84% were pigment production while 16% showed non-pigment producing Psedomonas as in [Table 12](#T12){ref-type="table"} and [Graph 12](#F18){ref-type="fig"}.

###### 

Demographic profile among all patients with *Pseudomonas* infection; 54% of patients were male, whereas 46% patients were female

  *Pseudomonas* species isolated   No. of samples (100)
  -------------------------------- ----------------------
  Male                             54%(54)
  Female                           46%(46)

![*Pseudomonas* infection was predominant in male compared to female](JFMPC-9-683-g007){#F7}

###### 

Distribution of *Pseudomonas* isolation from OPD/IPD of hospital; 39% of cases were indoor, whereas 61% were outdoor patients

  Samples from different departments (OPD/IPD)   No. of culture positive *Pseudomonas* samples
  ---------------------------------------------- -----------------------------------------------
  OPD                                            61%(61)
  IPD                                            39%(39)

![Rate of culture positive *Pseudomonas* samples from OPD and IPD](JFMPC-9-683-g008){#F8}

###### 

*Pseudomonas* infection was predominant in the age group of 46-60

  Different age groups with *Pseudomonas* infection   No. of *Pseudomonas* (out of 100)
  --------------------------------------------------- -----------------------------------
  0-15                                                05
  16-30                                               25
  31-45                                               29
  46-60                                               34
  \>60                                                07

![*Pseudomonas* infection was predominant in the age group of 46--60 years (34)](JFMPC-9-683-g009){#F9}

###### 

*Pseudomonas* infection was predominant in people residing in the urban areas (59%) as appose to those in rural areas (41%)

  Isolation of *Pseudomonas* from residential status   No. of *Pseudomonas* spp.
  ---------------------------------------------------- ---------------------------
  Urban                                                59% (59)
  Rural                                                41% (41)

###### 

Rate of *Pseudomonas* spp. from various clinical samples

      Specimen Type      No. of *Pseudomonas* stains (*n*=100)
  --- ------------------ ---------------------------------------
  1   Sputum             30
  2   Pus                50
  3   CSF                02
  4   Other body fluid   05
  5   Urine              10
  6   Blood              03

The maximum rate of *Pseudomonas* isolated from pus-50, sputum-30, urine-10, cerebral spinal fluid-02, other body fluid-05, blood-03

![Residential status of patients from urban and rural](JFMPC-9-683-g010){#F10}

![*Pseudomonas* species isolation from various clinical samples](JFMPC-9-683-g011){#F11}

###### 

Antibiotic resistance patterns of *Pseudomonas* spp; 88% and 80% resistances were encountered by ceftazidime and cefepime, followed by cortimoxazole and piperacillin showing 61% and 61%, respectively. The antibiotics showing least resistance were gentamycin, meropenem, and imepenem, the resistance being 30%, 17%, and 15%, respectively, and colistin showed 0% resistance

  Name of antibiotic               \% of antibiotic resistant *Pseudomonas* stains
  -------------------------------- -------------------------------------------------
  Piperacilin                      61%
  Ciproflaxacin                    46%
  Gentamycin                       30%
  Amikacin                         38%
  Tobramycin                       38%
  Cotrimoxazole                    61%
  Cefoperazone                     71%
  Cefepime                         80%
  Ceftazidime                      88%
  Ceftazidieme + Clavulanic acid   30%
  Meropenem                        17%
  Imipenem                         15%
  Colistin                         0%

![Antibiotic resistance patterns of *Psedomonas* species](JFMPC-9-683-g012){#F12}

###### 

Rate of ESBL positive samples out of total 100 samples studied; 42% were showing ESBL positive *Pseudomonas*, whereas 58% showed non-ESBL producing *Pseudomonas* species

  Total cases studied   No. of ESBL positive samples   No. of non-ESBL producing samples
  --------------------- ------------------------------ -----------------------------------
  100                   42 42%                         58 58%

![Rate of ESBL Positive samples](JFMPC-9-683-g013){#F13}

###### 

Distribution of ESBL producing *Pseudomonas* spp. from OPD and IPD

  Department of hospital (OPD/IPD)   No. of ESBL positive sample
  ---------------------------------- -----------------------------
  OPD                                20
  IPD                                22

![Distribution of ESBL producing *Pseudomonas* isolated from OPD/IPD of hospital](JFMPC-9-683-g014){#F14}

###### 

Gender-wise distribution of *Pseudomonas* spp. from various clinical isolations

  Age group (years)   Total no. of cases   \% of total case   Samples from sputum   Pus   Urine   Blood   CSF   Other body fluid                       
  ------------------- -------------------- ------------------ --------------------- ----- ------- ------- ----- ------------------ --- --- --- --- --- ---
  0-15                05                   5%                 2                     1     0       0       0     0                  1   1   0   0   0   0
  16-30               25                   25%                4                     5     5       9       0     1                  1   0   0   0   0   0
  31-45               29                   29%                4                     4     10      9       0     2                  0   0   0   0   0   0
  46-60               34                   34%                4                     5     9       8       3     2                  1   0   1   0   1   0
  \>60                7                    7%                 1                     0     0       0       1     1                  0   0   1   0   2   2
  Total               100                  100%               15                    15    24      26      4     6                  3   1   2   0   1   2

![Gender-wise distribution of *Pseudomonas* from various clinical isolations](JFMPC-9-683-g015){#F15}

###### 

Antibiotic resistance patterns of *Pseudomonas* against cephalosporin group of antibiotics. cefoperazone, cefepime, and ceftazidime showed high antibiotic resistance, whereas ceftaziime with combination of clavulanic acid showed less resistance

  Cephaloosporin group of antibiotics   Resistant   Intermediate   Sensitive
  ------------------------------------- ----------- -------------- -----------
  Cefoperazone                          71          2              27
  Cefepime                              80          2              18
  Ceftazidime                           88          0              14
  Ceftazidime + Ca                      30          0              70

###### 

Antibiotic resistance patterns of *Pseudomonas* against carbapenem group of antibiotics. Imipenem and meropenem demonstrated significantly higher antibacterial activity

  Carbapenem group of antibiotics   Resistant   Intermediate   Sensitive
  --------------------------------- ----------- -------------- -----------
  Imipenem                          15          2              83
  Meropenem                         17          11             72

![Antibiotic resistance patterns of *Pseudomonas* against cephalosporin group of antibiotics](JFMPC-9-683-g016){#F16}

![Antibiotic resistance patterns of *Pseudomonas* against carbapenem group of antibiotics](JFMPC-9-683-g017){#F17}

###### 

Rate of pigment and non-pigment producing *Pseudomonas* spp. Out of total 100 samples studied, 84% were pigment-producing, whereas 16% showed non-pigment producing *Pseudomonas*

  No. of total cases studied   No. of pigment-producing *Pseudomonas*   No. of non-pigment producing *Pseudomonas*
  ---------------------------- ---------------------------------------- --------------------------------------------
  100                          84 (84%)                                 16 (16%)

![Rate of pigment-producing and non-pigment producing *Pseudomonas* among 100 case studied](JFMPC-9-683-g018){#F18}

Discussion {#sec1-7}
==========

In recent times, emergence of antibiotic resistance has threatened the effectiveness of many antibiotic agents and it is recognized as a public health threat. *P. aeruginosa* which has particular propensity for drug resistance has been reported to be associated with increased mortality and morbidity.\[[@ref33]\] The incidence of *Pseudomonas* was higher in males than in females particularly after the age of 50 years.\[[@ref34]\]

Present study was conducted on 100 *Pseudomonas* isolation from various clinical sample. Out of which, 54 % of isolation was done from male and 46 were from female patients \[[Table 1](#T1){ref-type="table"} and [Graph 1](#F1){ref-type="fig"}\] and this was in concordance with the study conducted by Uslan DZ, Crane SJ *et al*.\[[@ref33]\] During the study period, 100 *Pseudomonas* isolates were recovered from a variety of specimens collected at the microbiology department. Out of 100 isolates 61% were from in patient department (IPD), while 39% of cases were from outpatient department (OPD) of the hospital \[[Table 2](#T2){ref-type="table"} and [Graph 2](#F2){ref-type="fig"}\] while in the study of Basak *et al*\[[@ref35]\] 81.6% *P. aeruginosa* strains were isolated from IPD.

In our study age-wise distribution of clinical isolates showed that *Pseudomonas* was common in the age group between 46-60 years. On comparison, we found that little difference in results in studies of Khan *et al*. (2008)\[[@ref34]\] and Rashid *et al*. (2007).\[[@ref36]\] It has been observed that age plays an important role in the patient\'s susceptibility to *Pseudomonas* infection i.e. maximum number of patient\'s were in age group of 46-60 years followed by 31-45 years and 16-30 years. This reason could be attributed to the facts that this age group (46-60) goes out of home and were at utmost risk to acquire an infection \[[Table 3](#T3){ref-type="table"} and [Graph 3](#F3){ref-type="fig"}\]. Etiology of *Pseudomonas* infection depends on various demographic characteristics that include the place of study (rural/urban). An area-wise distribution of *Pseudomonas* isolated was also analyzed. In this study, isolation of *Pseudomonas* was high in patients from urban areas 59% rather than in patients from rural areas 41% \[[Table 4](#T4){ref-type="table"} and [Graph 4](#F4){ref-type="fig"}\]. This may be because in rural areas people are less exposed to environmental problems that\'s way bacteria get less resistant. But in urban areas people are more exposed to environmental problems (air pollution, water pollution etc).

The distribution of specimens of *Pseudomonas* may vary with each hospital as each hospital facility has a different environment associated with it. More than 90% of the *Pseudomonas* isolates were obtained from pus, sputum, urine, and tracheal aspirates. Similar results had been obtained in different studies in India reported by Chander A *et al*., Mohanasoundaram and Arora *et al*.\[[@ref37][@ref38][@ref39]\] In this present study, the maximum number of *Pseudomonas* was isolated from pus was 50% (out of 100 samples), sputum 30%, urine 10%, and other body fluid 05% \[[Table 5](#T5){ref-type="table"} and [Graph 5](#F5){ref-type="fig"}\].

Pseudomonas spp. is inherently resistant to many antimicrobial agents, thus posing a great challenge in nosocomial infection. In the present study, antimicrobial susceptibility patterns of *Pseudomonas* from various clinical samples were analyzed for culture and sensitivity test. And 88% and 80% resistances were shown to ceftazidime and cefoperazone, \[[Table 6](#T6){ref-type="table"} and [Graph 6](#F6){ref-type="fig"}\]; however, least resistance, i.e. maximum sensitivity, was shown to gentamycin, meropenem, and imipenem which was also illustrated by Okesola *et al*.\[[@ref40]\] and Fam *et al*.\[[@ref41]\] Tavajjohi *et al*.\[[@ref42]\] and Roychaudhury *et al*.\[[@ref41]\] found resistance to imipenem and gentamycin in comparison to our study. Such increase in resistance could be due to the fact that Roychaudhury *et al*.\[[@ref43]\] included only patients who were on ventilator and taken several antibiotics before and, thus, developed resistance. There are only fewer studies reported in the literature regarding the etiology and antimicrobial susceptibility patterns of the *Pseudomonas* infections from particular geographical region.

In the present study of 100 samples, 42% cases were ESBL positive Pseudomonal bacteria, where as 58% showed growth of non-ESBL producing Psedomonas \[ \[[Table 7](#T7){ref-type="table"} and [Graph 7](#F7){ref-type="fig"}\] In Woodfort\[[@ref44]\] *et al* study in teritiary care hospital in China, 63.5% *Pseudomonas* were ESBL positive. In Yu *et al*\[[@ref45]\] study, 59% of isolates were ESBL positive and all isolates were susceptible to imipenem. Bajpai *et al*\[[@ref46]\] demonstrated a higher rate of culture positive isolation being 48% and Chen *et al*\[[@ref47]\] demonstrated a lower rate, i.e. 21%, this variation rate could be due to the regional variation.

In this study, ESBL positive *Pseudomonas* infection in IPD patients were 22% in comparison to OPD patients i.e. 20% \[[Table 8](#T8){ref-type="table"} and [Graph 8](#F8){ref-type="fig"}\]. It may be due to healthcare issues in hospitalized patients. A similar observation was made by Anupurba S *et al*.,\[[@ref48]\] who reported the isolation of *P. aeruginosa* to be more common in IPD patients 42% compared to that in the OPD cases 26.57%. They expressed their view that the duration of hospital stay was directly proportional to a higher prevalence of the infection because the rate of isolation of the organism was higher in IPD patients than in OPD patients.

*P. aeruginosa* is inherently resistant to many antimicrobial agents, mainly due to the synergy between multidrug efflux system or a type 1 AmpC β-lactamase and low outer membrane permeability. The age and sex wise distribution of patients diagnosed with ESBL positive *Pseudomonas* infection followed the natural epidemiological pattern.\[[@ref49]\] Out of 100 sample 42% was ESBL positive *Pseudomonas* and 58% was non ESBL producing *Pseudomonas*. The maximum non ESBL producing *Pseudomonas* were isolated from females \[[Table 9](#T9){ref-type="table"} and [Graph 9](#F9){ref-type="fig"}\] and in case of urine samples female has more number of ESBL positive *Pseudomonas*.

The incidence of UTI by *Pseudomonas* is greater in women than man, which may be either due to anatomical predisposition or urolithial mucosal adherence to mucopolysaccharide lining or other host factors.\[[@ref49][@ref50]\] The dose, as well as the incidence of toxicity, was subsequently reduced with semisynthetic penicillins like ticarcillin, which makes it the preferred ureidopenicillin against *Pseudomonas* infections. Our results are in corroboration with the one reported by other workers, SV Chitnis *et al*\[[@ref51]\] so much so that the overall resistance to various generations of cephalosporin was high on account of the production of ESBL by the bacteria involved P. Mathur *et al*\[[@ref52]\] in percent study Ceftazidime was 88% resistant, 0% intermediate, and 14% sensitive (maximum resistance) and ceftazidime + clavulanic acid 30% resistance, 0% intermediate, and 70% sensitive (maximum sensitive) \[[Table 10](#T10){ref-type="table"} and [Graph 10](#F10){ref-type="fig"}\].

In our study, notable resistance to *Pseudomonas* was observed against carbapenems. The resistance to carbapenems, especially in *Pseudomonas*, results from reduced levels of drug accumulation or increased expression of pump efflux.\[[@ref53][@ref54]\] The resistance may also be due to the production of ESBL or MBL, which can be chromosomally encoded or plasmid-mediated.\[[@ref55]\] The carbapenem hydrolyzing enzyme carbapenamase may be class B-extended spectrum β-lactamases or class D-oxacillanases or class A-clavulanic acid inhibitory enzymes.\[[@ref56]\] In percent study, imipenem is more sensitive to *Pseudomonas*; it was 15% resistance, 2% intermediate, and 83% of sensitive (maximum sensitive to carbapenem group of antibiotics) and for meropenem it was 17% resistance, 11% intermediate, and 72% sensitive. \[[Table 11](#T11){ref-type="table"} and [Graph 11](#F11){ref-type="fig"}\] Imipenem and meropenem were also found to be the most effective antibiotics against the ESBL-producing *P. aeruginosa* isolates in the study of Shaikh *et al*.\[[@ref57]\]

In the present was showed number of pigment producing *Pseudomonas* is more in comparison to non-pigment producing *Pseudomonas*. The pigment producing *Pseudomonas* is 84% in comparison to non-pigment producing which were 16% \[[Table 12](#T12){ref-type="table"} and [Graph 12](#F12){ref-type="fig"}\]. Finlayson EA *et al*\[[@ref58]\] stated that antibiotic resistance might not be associated with the pigment producing *Pseudomonas*. However, pigment production appeared to be more significantly associated with multidrug-resistant, presence of virulence-associated gene, and expression of certain virulence factors, most notably elastase, protease, siderophore, and DNase activity. Since pigment production is easy to determine, this might to be a good starting point to identify the virulence status of an isolate. Resistant to different antibiotics (amoxicillin/clavulinic, sulphamethaxzole/trimethoprim, doxycycline and ceftazidime) determined by disc diffusion method was also seen in the study of Abbas *et al*. in 266 urine samples and concluded that the resistance rates in *P. aeruginosa* were higher than global values.\[[@ref59]\]

Conclusion {#sec1-8}
==========

To conclude, the present study highlights that the *Pseudomonas* species remains an important cause of nosocomial infections. ESBL producing *Pseudomonas* species continue to be an important organism causing life-threatening infections. Multidrug resistance was seen in most of the stains and even to combination of ceftazidime clavulanic acid the resistance was seen. Resistance is developing to imipenem also. This gives the alarming signal for the future making the therapeutic options more difficult. Strict infection control measures are to be taken to contain this so-called water and soil organisms as *Pseudomonas*. This article can bring the drugs of choice to clinicians in the treatment and primary care of patient with *Pseudomonas* infection and help to avoid excessive and injudicious use of extended-spectrum cephalosporins and carbapenems in every hospital. Urgent work is required to develop quicker, cost-effective, and reliable diagnostic tools as well as new effective therapies and proper antibiotic policies should be formulated for the effective defenses against this organism.
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